Amazon using its scale, consumer focus to reimagine primary care, Care Medical exec says Moderna CEO Bancel set for a soft landing as his golden parachute swells to $926M FDA slams Philips' 'inadequate' efforts to notify patients, suppliers of CPAP recall Capricor culls COVID-19 vax work but eyes phase 3 for Duchenne therapy Immunome's COVID-19 antibody cocktail back on track for phase 1 after FDA lifts hold Ramping up domestic production won't solve US medical supply chain challenges: report Pfizer's softly, softly, COVID marketing approach continues with new drug ad Medtronic taps Apple partner Rockley Photonics to build biomarker-sensing wearables Amid inflation spike, execs at J&J, Bayer, GSK and more talk higher costs—and what it means for profits Texas, southern states had large spikes in ACA coverage for 2022 thanks to boosted subsidies Histogen seeks to tear up COVID-19 R&D pact and go solo, accuses Amerimmune of failing to push on into phase 2 RISE 2022: Don't expect COVID-19 to be done as wave dissipates, former CDC official Nancy Messonnier says RefleXion collects $80M after scoring breakthrough tag for its PET-guided radiotherapy Concert tunes pipeline by selling off CNS assets to startup Terran Biosciences Stevanato's growth spree rolls on with China plant purchase, plans for 270 jobs Featured Story | By Heather Landi MIAMI—Sunita Mishra, M.D., spent more than 15 years in medical practice as an internist and primary care doctor and then moved over to Amazon Care to serve as the medical director at Care Medical. Here's why Mishra is bullish on Amazon's ability to use its scale and consumer-centric focus to build a "world-class patient experience." read more |
| |
|---|
|
Top Stories By Kevin Dunleavy Moderna CEO Stéphane Bancel's golden parachute now clocks in at $926 million, the company revealed in its proxy report earlier this week. The news comes after a transformational year for the company as its revenues went from $803 million in 2020 to $18.5 billion last year amid its worldwide COVID-19 vaccine launch. read more By Andrea Park Nine months into Philips’ wide-ranging Class I recall of many of its CPAP and BiPAP machines and other respiratory devices, the FDA isn’t entirely pleased with how the company has handled the recall. read more By Kyle LaHucik Capricor Therapeutics will get enrollment underway in a phase 3 trial for its Duchenne muscular dystrophy cell therapy next quarter, while development of a COVID-19 vaccine is coming to a halt. read more By Max Bayer Immunome’s antibody cocktail COVID-19 treatment is free from an FDA hold, two months after the pause was first placed. read more By Anastassia Gliadkovskaya While it’s no secret how heavily the U.S. relies on other countries for medical imports, the report challenged the widely suggested solution of increasing domestic production as a way of increasing supply chain resilience. read more By Ben Adams Pfizer’s COVID vaccine ads have been light on branding and strong on “human spirit,” and that subtle marketing approach continues—though with a small difference—in its first commercial for COVID-fighting pills. read more By Andrea Park The partnership will combine Rockley’s recently launched biosensing technology and Medtronic’s decades of experience developing patient-facing tools and services. read more By Eric Sagonowsky While inflation is top of consumers' minds right now, pharma companies are also feeling the pain of higher prices when it comes to profit margins. During recent discussions with analysts, execs with Johnson & Johnson, Bayer, GlaxoSmithKline and more talked about the higher prices facing their businesses. read more By Robert King Texas and several other southern states saw increases of 30% or more in sign-ups for 2022 Affordable Care Act coverage, with sign-ups boosted by enhanced subsidies that expire after this year. read more By Nick Paul Taylor The collaboration between Histogen and Amerimmune has soured. Believing Amerimmune has failed to meet its R&D responsibilities, Histogen is seeking to terminate the collaboration agreement and retake control of the COVID-19 development program. read more By Robert King NASHVILLE, Tenn.—Former CDC official Nancy Messonnier told the crowd at RISE 2022 that the worst of the omicron COVID-19 surge is over but the pandemic is not done yet. read more By Conor Hale Radiotherapy specialist RefleXion Medical has raised $80 million to help broaden its cancer offerings after recently exploring the company’s potential in treating prostate cancer and other tumors. read more By Kyle LaHucik A new act is coming in to swoop up Concert Pharmaceuticals' audience as the biotech sells some central nervous system assets to little known startup Terran Biosciences. read more By Kevin Dunleavy A week after Italian vials manufacturer Stevanato announced a $95 million deal with the U.S. government to expand operations at its facility under construction in Fishers, Indiana, the company says it has acquired a plant in Zhangjiagang, China, which it will expand to 32,000 square feet. read more |
